Literature DB >> 25730187

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available.

S Garciaz1, L Castagna2, R Bouabdallah1, S Fürst1, S Bramanti2, D Coso1, R Crocchiolo2, J El-Cheikh1, F Broussais1, C Chabannon1, A Santoro2, D Blaise1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25730187     DOI： 10.1038/bmt.2015.22

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.

Authors:  Christopher G Kanakry; Paul V O'Donnell; Terry Furlong; Marcos J de Lima; Wei Wei; Marta Medeot; Marco Mielcarek; Richard E Champlin; Richard J Jones; Peter F Thall; Borje S Andersson; Leo Luznik
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

2.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

Review 3.  High-dose cyclophosphamide for graft-versus-host disease prevention.

Authors:  Leo Luznik; Richard J Jones; Ephraim J Fuchs
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

4.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

Authors:  Yvette L Kasamon; Leo Luznik; Mary S Leffell; Jeanne Kowalski; Hua-Ling Tsai; Javier Bolaños-Meade; Lawrence E Morris; Pamela A Crilley; Paul V O'Donnell; Nancy Rossiter; Carol Ann Huff; Robert A Brodsky; William H Matsui; Lode J Swinnen; Ivan Borrello; Jonathan D Powell; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-18       Impact factor: 5.742

Review 5.  Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.

Authors:  Leo Luznik; Paul V O'Donnell; Ephraim J Fuchs
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

6.  Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.

Authors:  Marcelo C Pasquini; Steven Devine; Adam Mendizabal; Lindsey R Baden; John R Wingard; Hillard M Lazarus; Frederick R Appelbaum; Carolyn A Keever-Taylor; Mary M Horowitz; Shelly Carter; Richard J O'Reilly; Robert J Soiffer
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

7.  Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Authors:  Anna Maria Raiola; Alida Dominietto; Carmen di Grazia; Teresa Lamparelli; Francesca Gualandi; Adalberto Ibatici; Stefania Bregante; Maria Teresa Van Lint; Riccardo Varaldo; Anna Ghiso; Marco Gobbi; Angelo Michele Carella; Alessio Signori; Federica Galaverna; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-05       Impact factor: 5.742

8.  Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Authors:  Anne Sirvent; Nathalie Dhedin; Mauricette Michallet; Nicolas Mounier; Catherine Faucher; Ibrahim Yakoub-Agha; Mohamad Mohty; Marie Robin; Reza Tabrizi; Laurence Clement; Karin Bilger; Fabrice Larosa; Nathalie Contentin; Anne Huyn; Sylvie François; Claude-Eric Bulabois; Patrice Ceballos; Jean-Henri Bourrhis; Agnès Buzyn; Jérôme Cornillon; Gaelle Guillerm; Thierry de Revel; Jacques-Olivier Bay; François Guilhot; Noël Milpied
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-08       Impact factor: 5.742

9.  Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.

Authors:  Brian L McClune; Kwang Woo Ahn; Hai-Lin Wang; Joseph H Antin; Andrew S Artz; Jean-Yves Cahn; Abhinav Deol; César O Freytes; Mehdi Hamadani; Leona A Holmberg; Madan H Jagasia; Ann A Jakubowski; Mohamed A Kharfan-Dabaja; Hillard M Lazarus; Alan M Miller; Richard Olsson; Tanya L Pedersen; Joseph Pidala; Michael A Pulsipher; Jacob M Rowe; Wael Saber; Koen W van Besien; Edmund K Waller; Mahmoud D Aljurf; Görgun Akpek; Ulrike Bacher; Nelson J Chao; Yi-Bin Chen; Brenda W Cooper; Jason Dehn; Marcos J de Lima; Jack W Hsu; Ian D Lewis; David I Marks; Joseph McGuirk; Mitchell S Cairo; Harry C Schouten; Jeffrey Szer; Muthalagu Ramanathan; Bipin N Savani; Matthew Seftel; Gérard Socie; Ravi Vij; Erica D Warlick; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-15       Impact factor: 5.742

10.  Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.

Authors:  Andrew R Rezvani; Barry Storer; Michael Maris; Mohamed L Sorror; Edward Agura; Richard T Maziarz; James C Wade; Thomas Chauncey; Stephen J Forman; Thoralf Lange; Judith Shizuru; Amelia Langston; Michael A Pulsipher; Brenda M Sandmaier; Rainer Storb; David G Maloney
Journal:  J Clin Oncol       Date:  2007-12-03       Impact factor: 44.544
View more
  4 in total

1.  Related haploidentical donors are a better choice than matched unrelated donors: Point.

Authors:  Ephraim Joseph Fuchs
Journal:  Blood Adv       Date:  2017-02-14

Review 2.  Modern approaches to HLA-haploidentical blood or marrow transplantation.

Authors:  Christopher G Kanakry; Ephraim J Fuchs; Leo Luznik
Journal:  Nat Rev Clin Oncol       Date:  2015-08-25       Impact factor: 66.675

3.  T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.

Authors:  R Devillier; S Bramanti; S Fürst; B Sarina; J El-Cheikh; R Crocchiolo; A Granata; C Chabannon; L Morabito; S Harbi; C Faucher; A Santoro; P-J Weiller; N Vey; C Carlo-Stella; L Castagna; D Blaise
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

Review 4.  Haploidentical Stem Cell Transplantation in Lymphomas-Expectations and Pitfalls.

Authors:  Jacopo Mariotti; Stefania Bramanti; Armando Santoro; Luca Castagna
Journal:  J Clin Med       Date:  2020-11-07       Impact factor: 4.241
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.